Defeated Icahn sells Visx stake
This article was originally published in Clinica
Laser vision correction firm Visx has finally shaken off the attentions of financier Carl Icahn, who recently failed to gain board representation with the aim of securing a buyer for the firm (see Clinica No 1059, p 13). Mr Icahn has sold an 11.8% stake in the firm, amounting to some 6 million shares.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.